Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
10 December 2018 | Story Leonie Bolleurs | Photo Leonie Bolleurs
One step closer to treat HIV/Aids
Nthabiseng Mokoena is working on an article based on her research about drug development in infection models, which will be published under the Research Chair in Pathogenic Yeasts.

South Africa has the biggest and most high-profile HIV epidemic in the world, with an estimated seven million people living with HIV in 2015. In the same year, there were 380 000 new infections while 180 000 South Africans died from AIDS-related illnesses. 

Invasive fungal infection, common in certain groups of patients with immune deficits, is a serious driver of global mortality in the context of the global HIV pandemic. 

“Despite a major scientific effort to find new cures and vaccines for HIV, hundreds of thousands of HIV-infected individuals continue to die on a yearly basis from secondary fungal infection. Intensive research needs to be done to help reduce the unacceptably high mortality rate due to the infection in South Africa,” said Nthabiseng Mokoena.

Mokoena is a master’s student of Prof Carlien Pohl-Albertyn, who is heading the Research Chair in Pathogenic Yeasts in the Department of Microbial, Biochemical and Food Biotechnology at the University of the Free State (UFS). 

She received her master’s degree at the December graduations of the UFS. Her thesis is titled: Caenorhabditis elegans as a model for Candida albicans-Pseudomonas aeruginosa co-infection and infection induced prostaglandin production.

Research Chair in Pathogenic Yeasts

Earlier this year, the National Research Foundation approved the Research Chair in Pathogenic Yeasts. One of the projects of the group of scientists in this chair include a study of the interaction between the yeast, Candida albicans and the bacterium, Pseudomonas aeruginosa in different hosts, using a variety of infection models.

In her research, Mokoena studied the response of infectious pathogens such as yeasts and bacteria, using a nematode (little roundworm) as an infection model to mimic the host environment. Nematodes have a number of traits similar to humans. It is thus a good alternative for humans as infection models, as it is unethical to use the latter.

Nematodes have a number of advantages, including its low cost and fast reproduction and growth. 

Mokoena monitored the survival of the nematodes to see how infectious the pathogens are, especially in combination with each other. 

Role of infection model for drug development

When these two pathogens were studied in a lab (in vitro), it was found that they can inhibit each other, but after studying them in the infection model (in vivo), Mokoena showed that these pathogens are more destructive together. 

This finding has a huge impact for the pharmaceutical industry, as it can provide information on how drugs need to be designed in order to fight infectious diseases where multiple organisms cause co-infections.

Many pathogens are resistant to drugs. Through this model, drugs can be tested in a space similar to the human body. Seeing how pathogens react to drugs within a space similar to the human body, can contribute to drug development. 

Not only are drugs developed more effectively through this model, it is also less expensive. 

It is the first time that the combination of the yeast, Candida albicans and the bacterium, Pseudomonas aeruginosa, is being experimented on in this model. 

News Archive

Shuttle services for senior medical students
2011-09-26

 

Senior medical students who make use of the shuttle services are standing next to the mini-bus.

On Friday, 30 September 2011, our university will officially launch its shuttle service for medical students. This function will take place from 12:00 to 13:00 at the Faculty of Health Sciences’ CJC Nel Reception Venue in the Francois Retief Building on our Bloemfontein Campus.

Two years ago. Dr Scarpa Schoeman began working at Internal Medicine at our Faculty of Health Sciences. Early on, he identified the transport problems of fourth- and fifth-year medical students (Phase-3 students) in the English class.
 
There are 65 Phase-3 students in the English class who are currently struggling with transport and who are part of this project. About 90% of them are bursary students at the university who, according to Schoeman, are consequently also struggling with finances. These students used public transport like taxis to move between hospital rounds and classes in the past. On average, it would cost them up to R4 000 per year for these daily travels between the UFS and the various training hospitals.
 
By the end of March 2011, NetCare had donated two mini-busses to the UFS and since 11 April, the shuttle services were available to medical students. Prof. Gert van Zyl (Dean of our Faculty of Health Sciences), Mr Mickey Gordon (Head: Marketing, Institutional Advancement and Sport) and the Rector, Prof. Jonathan Jansen, negotiated with NetCare. Gordon was also responsible for the branding of the busses. PPS and Pfizer are both sponsors who contributed to this.
 
This project is managed by Dr Schoeman, assisted by Mrs Anne-Marie Nel, who handles the administration as the Phase-3 secretary.
 
“It is important for us from the project management that students won’t see this as another taxi, but as a shuttle service of the university. Any senior medical student may make use of it, but it is mainly the under-privileged student from the English class who makes use of it.”
 
The two Quantum mini-busses do the circuit according to fixed schedules each day.  The route starts at the Francois Retief Building on our Bloemfontein Campus and then travels to the National Hospital, the Free State Psychiatric Complex (Oranje), Pelonomi, 3 Military Hospital (at Tempe) and then back again to Universitas Hospital.

 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept